Analysis of Skin Cancer Treatment and Costs in the United States Medicare Population, 1996–2008

Authors


  • The authors have indicated no significant interest with commercial supporters.

Address correspondence and reprint requests to: Howard W. Rogers, MD, PhD, Advanced Dermatology, 111 Salem Turnpike, Suite 7, Norwich, CT 06360, or e-mail: rogershoward@sbcglobal.net

Abstract

Background

There is a skin cancer epidemic in the United States.

Objective

To examine skin cancer treatment modality, location, and cost and physician specialty in the Medicare population from 1996 to 2008.

Methods

Centers for Medicare and Medicaid Services databases were used to examine skin cancer treatment procedures performed for Medicare beneficiaries.

Results

From 1996 to 2008, the total number of skin cancer treatment procedures [malignant excision, destruction, and Mohs micrographic surgery (MMS)] increased from 1,480,645 to 2,152,615 (53% increase). The numbers of skin cancers treated by excision and destruction increased modestly (20% and 39%, respectively), but the number of MMS procedures increased more rapidly (248% increase). Dermatologists treated an increasing percentage (75–82%) of skin cancers during these years, followed by plastic and general surgery. In 2008, more than 90% of all skin cancers were treated in the office, with the remainder being treated in facility-based settings. Allowable charges paid to physicians by Medicare Part B for skin cancer treatments increased 137% from 1996 to 2008, from $266,960,673 to $633,448,103.

Conclusions

The number of skin cancer treatment procedures increased substantially from 1996 to 2008, as did overall costs to Medicare. Dermatologists treated the vast majority of skin cancers in the Medicare population, using a mix of treatment modalities, almost exclusively in the office setting.

Ancillary